ABBV

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784725971.7de6d7f

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784725973.7de8ff7

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784725976.7deb41f

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

abbv-202602040001551152false00015511522026-02-042026-02-040001551152us-gaap:CommonStockMemberexch:XNYS2026-02-042026-02-040001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec1250SeniorNotesDue2031Memberexch:XNYS2026-02-042026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2026

ABBVIE INC.

(Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.  Results of Operations and Financial Condition

On February 4, 2026, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated February 4, 2026 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:February 4, 2026By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202601070001551152false00015511522026-01-072026-01-070001551152us-gaap:CommonStockMemberexch:XNYS2026-01-072026-01-070001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2026-01-072026-01-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2026

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2025 are expected to include acquired IPR&D and milestones expense of $1.3 billion on a pre-tax basis, representing an unfavorable impact of $0.71 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on October 31, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2025 acquired IPR&D and milestones expense, is $9.90 - $9.94. AbbVie’s fourth quarter 2025 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2025 acquired IPR&D and milestones expense, is $2.61 - $2.65.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the fourth quarter of 2025.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under the Exchange Act or under the Securities Act of 1933, as a

abbv-202510310001551152false00015511522025-10-312025-10-310001551152us-gaap:CommonStockMemberexch:XNYS2025-10-312025-10-310001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-10-312025-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

On October 31, 2025, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated October 31, 2025 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:October 31, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202510030001551152false00015511522025-10-032025-10-030001551152us-gaap:CommonStockMemberexch:XNYS2025-10-032025-10-030001551152us-gaap:CommonStockMemberexch:XCHI2025-10-032025-10-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-10-032025-10-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-10-032025-10-030001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-10-032025-10-030001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-10-032025-10-030001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-10-032025-10-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis, representing an unfavorable impact of $1.50 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on July 31, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of third quarter 2025 acquired IPR&D and milestones expense, is $10.38 - $10.58. AbbVie’s third quarter 2025 adjusted diluted earnings per share guidance range, including the impact of third quarter 2025 acquired IPR&D and milestones expense, is $1.74 - $1.78.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the third quarter of 2025.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under

abbv-202507310001551152false00015511522025-07-312025-07-310001551152us-gaap:CommonStockMemberexch:XNYS2025-07-312025-07-310001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-07-312025-07-310001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-07-312025-07-310001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-07-312025-07-310001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-07-312025-07-310001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-07-312025-07-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

On July 31, 2025, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June 30, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated July 31, 2025 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:July 31, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202507030001551152false00015511522025-07-032025-07-030001551152us-gaap:CommonStockMemberexch:XNYS2025-07-032025-07-030001551152us-gaap:CommonStockMemberexch:XCHI2025-07-032025-07-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-07-032025-07-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 3, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on April 25, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is $11.67 - $11.87. AbbVie’s second quarter 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is $2.84 - $2.88.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the second quarter of 2025.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under th

abbv-202504250001551152false00015511522025-04-252025-04-250001551152exch:XNYSus-gaap:CommonStockMember2025-04-252025-04-250001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2025-04-252025-04-250001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2025-04-252025-04-250001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2025-04-252025-04-250001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2025-04-252025-04-250001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2025-04-252025-04-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

On April 25, 2025, AbbVie Inc. issued a press release announcing financial results for the first quarter ended March 31, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated April 25, 2025 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:April 25, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202504030001551152false00015511522025-04-032025-04-030001551152exch:XCHIus-gaap:CommonStockMember2025-04-032025-04-030001551152exch:XNYSus-gaap:CommonStockMember2025-04-032025-04-030001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2025-04-032025-04-030001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2025-04-032025-04-030001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2025-04-032025-04-030001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2025-04-032025-04-030001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2025-04-032025-04-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 3, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis, representing an unfavorable impact of $0.13 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on January 31, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred in 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of first quarter 2025 acquired IPR&D and milestones expense, is $11.99 - $12.19. AbbVie’s first quarter 2025 adjusted diluted earnings per share guidance range, including the impact of first quarter 2025 acquired IPR&D and milestones expense, is $2.34 - $2.38. This guidance does not reflect the impact related to AbbVie and Gubra’s licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the first quarter of 2025.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as ame

abbv-202501310001551152false00015511522025-01-312025-01-310001551152exch:XCHIus-gaap:CommonStockMember2025-01-312025-01-310001551152exch:XNYSus-gaap:CommonStockMember2025-01-312025-01-310001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2025-01-312025-01-310001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2025-01-312025-01-310001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2025-01-312025-01-310001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2025-01-312025-01-310001551152exch:XNYSabbv:Sec1250SeniorNotesDue2031Member2025-01-312025-01-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 31, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.  Results of Operations and Financial Condition

On January 31, 2025, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2024.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated January 31, 2025 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:January 31, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202501060001551152false00015511522025-01-062025-01-060001551152exch:XNYSus-gaap:CommonStockMember2025-01-062025-01-060001551152exch:XCHIus-gaap:CommonStockMember2025-01-062025-01-060001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2025-01-062025-01-060001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2025-01-062025-01-060001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2025-01-062025-01-060001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2025-01-062025-01-060001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2025-01-062025-01-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 6, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&D and milestones expense of $1.6 billion on a pre-tax basis, representing an unfavorable impact of $0.88 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on October 30, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2024 acquired IPR&D and milestones expense, is $10.02 - $10.06. AbbVie’s fourth quarter 2024 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2024 acquired IPR&D and milestones expense, is $2.06 - $2.10.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the fourth quarter of 2024.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings b

abbv-202410300001551152false00015511522024-10-302024-10-300001551152exch:XNYSus-gaap:CommonStockMember2024-10-302024-10-300001551152exch:XCHIus-gaap:CommonStockMember2024-10-302024-10-300001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-10-302024-10-300001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-10-302024-10-300001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-10-302024-10-300001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-10-302024-10-300001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-10-302024-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2024

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

On October 30, 2024, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2024.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated October 30, 2024 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:October 30, 2024By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202410030001551152false00015511522024-10-032024-10-030001551152exch:XNYSus-gaap:CommonStockMember2024-10-032024-10-030001551152exch:XCHIus-gaap:CommonStockMember2024-10-032024-10-030001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-10-032024-10-030001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-10-032024-10-030001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-10-032024-10-030001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-10-032024-10-030001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-10-032024-10-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2024

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2024 are expected to include acquired IPR&D and milestones expense of $82 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on August 1, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of third quarter 2024 acquired IPR&D and milestones expense, is $10.67 - $10.87. AbbVie’s third quarter 2024 adjusted diluted earnings per share guidance range, including the impact of third quarter 2024 acquired IPR&D and milestones expense, is $2.88 - $2.92.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the third quarter of 2024.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbV

abbv-202407250001551152false00015511522024-07-252024-07-250001551152exch:XCHIus-gaap:CommonStockMember2024-07-252024-07-250001551152us-gaap:CommonStockMemberexch:XNYS2024-07-252024-07-250001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-07-252024-07-250001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-07-252024-07-250001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2024-07-252024-07-250001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2024-07-252024-07-250001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2024-07-252024-07-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 25, 2024

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

On July 25, 2024, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June 30, 2024.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated July 25, 2024 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:July 25, 2024By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202407030001551152false00015511522024-07-032024-07-030001551152us-gaap:CommonStockMemberexch:XCHI2024-07-032024-07-030001551152us-gaap:CommonStockMemberexch:XNYS2024-07-032024-07-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2024-07-032024-07-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2024-07-032024-07-030001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-07-032024-07-030001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-07-032024-07-030001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-07-032024-07-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 3, 2024

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2024 are expected to include acquired IPR&D and milestones expense of $937 million on a pre-tax basis, representing an unfavorable impact of $0.52 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on April 26, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of second quarter 2024 acquired IPR&D and milestones expense, is $10.61 - $10.81. AbbVie’s second quarter 2024 adjusted diluted earnings per share guidance range, including the impact of second quarter 2024 acquired IPR&D and milestones expense, is $2.53 - $2.57.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the second quarter of 2024.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie

abbv-202404260001551152false00015511522024-04-262024-04-260001551152us-gaap:CommonStockMemberexch:XNYS2024-04-262024-04-260001551152exch:XCHIus-gaap:CommonStockMember2024-04-262024-04-260001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2024-04-262024-04-260001551152exch:XNYSabbv:Sec1250SeniorNotesDue2024Member2024-04-262024-04-260001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-04-262024-04-260001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2024-04-262024-04-260001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2024-04-262024-04-260001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-04-262024-04-260001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2024-04-262024-04-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2024

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

On April 26, 2024, AbbVie Inc. issued a press release announcing financial results for the first quarter ended March 31, 2024.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated April 26, 2024 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:April 26, 2024By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer

abbv-202404030001551152false00015511522024-04-032024-04-030001551152us-gaap:CommonStockMemberexch:XCHI2024-04-032024-04-030001551152us-gaap:CommonStockMemberexch:XNYS2024-04-032024-04-030001551152exch:XNYSabbv:Sec1.375SeniorNotesDue2024Member2024-04-032024-04-030001551152abbv:Sec1250SeniorNotesDue2024Memberexch:XNYS2024-04-032024-04-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2024-04-032024-04-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2024-04-032024-04-030001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-04-032024-04-030001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-04-032024-04-030001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-04-032024-04-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 3, 2024

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange

1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2024 are expected to include acquired IPR&D and milestones expense of $164 million on a pre-tax basis, representing an unfavorable impact of $0.08 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on February 12, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred in 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of first quarter 2024 acquired IPR&D and milestones expense, is $10.97 - $11.17. AbbVie’s first quarter 2024 adjusted diluted earnings per share guidance range, including the impact of first quarter 2024 acquired IPR&D and milestones expense, is $2.18 - $2.22.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the first quarter of 2024.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not

abbv-202402020001551152false00015511522024-02-022024-02-020001551152exch:XCHIus-gaap:CommonStockMember2024-02-022024-02-020001551152exch:XNYSus-gaap:CommonStockMember2024-02-022024-02-020001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2024-02-022024-02-020001551152exch:XNYSabbv:Sec1250SeniorNotesDue2024Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec1250SeniorNotesDue2031Member2024-02-022024-02-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2024

ABBVIE INC.

(Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation)   Identification No.)

1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange 1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.  Results of Operations and Financial Condition

On February 2, 2024, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Exhibit 99.1 Press Release dated February 2, 2024 (furnished pursuant to Item 2.02).

104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:February 2, 2024By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer